Advancing cell & gene therapy – optimizing lentiviral vector design and production

To meet the demand for innovative treatments based on cell therapy, it’s essential that we deliver solutions that are both faster and more cost-effective. Optimizing lentiviral vector (LVV) design and production is critical for advancing a subset of these therapies like CAR-T.

The primary challenge lies in developing scalable production systems that achieve high viral titers while ensuring the purity and stability of viral vectors to preserve safety and efficacy. Moreover, compliance with stringent regulatory requirements is paramount.

In this symposium, we will address key questions facing the biotech industry today: What are some of the main challenges in improving cutting-edge manufacturing techniques? How can we boost LVV yield and enhance safety profiles? What insights can we gain from viral vector production applied in other areas like vaccines and gene therapy?

Join us during this Johnson & Johnson Innovation – JLABS program as we delve into the latest advancements in viral vector production, focusing specifically on lentiviral vectors. We will also explore potential future developments and identify bottlenecks that may hinder implementation. Through collaboration and ongoing research, we aim to overcome these challenges and unlock the full potential of cell therapies, paving the way for innovative treatments that improve patient outcomes and benefit healthcare systems worldwide.